Adaptive Biotechnologies Corp
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
ADPT$29.36-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(20,015) | $(29,830) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation expense | 3,418 | 4,312 |
| Noncash lease expense | 1,448 | 1,311 |
| Share-based compensation expense | 11,928 | 12,147 |
| Intangible assets amortization | 419 | 419 |
| Investment amortization | (136) | (958) |
| Impairment of long-lived assets | 347 | — |
| Write-off of inventory | (10) | (101) |
| Revenue interest purchase agreement interest | (655) | 283 |
| Other | 14 | 76 |
| Changes in operating assets and liabilities | ||
| Accounts receivable, net | 2,050 | (1,864) |
| Inventory | (1,315) | 264 |
| Prepaid expenses and other current assets | (824) | 489 |
| Accounts payable and accrued liabilities | (7,512) | (9,665) |
| Operating lease right-of-use assets and liabilities | (2,600) | (2,035) |
| Deferred revenue | 4,004 | (3,326) |
| Other | (98) | (6) |
| Net cash used in operating activities | (9,537) | (28,484) |
| Investing activities | ||
| Purchases of property and equipment | (796) | (1,259) |
| Purchases of marketable securities | (38,863) | (50,654) |
| Proceeds from maturities of marketable securities | 48,802 | 77,486 |
| Net cash provided by investing activities | 9,143 | 25,573 |
| Financing activities | ||
| Proceeds from exercise of stock options | 5,025 | 5,451 |
| Proceeds from capital contributions for Digital Biotechnologies, Inc. | 2,475 | — |
| Cash provided by financing activities | 7,500 | 5,451 |
| Net increase in cash, cash equivalents and restricted cash | 7,106 | 2,540 |
| Cash, cash equivalents and restricted cash at beginning of year | 73,184 | 50,817 |
| Cash, cash equivalents and restricted cash at end of period | $80,290 | $53,357 |
| Noncash investing activities | ||
| Purchases of equipment included in accounts payable and accrued liabilities | $159 | $211 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $3,584 | $2,373 |
| Reconciliation of cash, cash equivalents and restricted cash at end of period | ||
| Cash and cash equivalents at end of period | $77,581 | $50,646 |
| Restricted cash at end of period | 2,709 | 2,711 |
| Total cash, cash equivalents and restricted cash at end of period | $80,290 | $53,357 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.